We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0LC7 market cap is 251.96M. The company's latest EPS is USD -7.8119 and P/E is -0.03.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.98M | 15.09M | 23.49M | 14.88M | 9.94M |
| Operating Income | -77.74M | -82.3M | -99.42M | -135.87M | -128.99M |
| Net Income | -75.44M | -84.04M | -86.56M | -94.65M | -164.57M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 149.98M | 213.25M | 182.94M | 244.49M | 168.17M |
| Total Liabilities | 70.79M | 122.7M | 97.72M | 116.75M | 151.51M |
| Total Equity | 79.18M | 90.55M | 85.22M | 127.74M | 16.66M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -60.25M | -57.36M | -99.54M | -123.07M | -109.71M |
| Investing | -11.73M | 46.66M | -52.65M | 67.19M | 37.34M |
| Financing | 65.99M | 142.95M | 70.51M | 131.05M | 43.46M |
| Market Cap | 251.96M |
| Price to Earnings Ratio | -0.03 |
| Price to Sales Ratio | 0.55 |
| Price to Cash Ratio | 0.04 |
| Price to Book Ratio | 0.33 |
| Dividend Yield | - |
| Shares Outstanding | 21.07M |
| Average Volume (1 week) | 643.95k |
| Average Volume (1 Month) | 1.32M |
| 52 Week Change | 0.00% |
| 52 Week High | 11.96 |
| 52 Week Low | 11.96 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Syros Pharmaceuticals Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.syros.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
